Inhibition of Epstein-Barr virus replication by a benzimidazole L- riboside: Novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-β- L-ribofuranosyl-1H-benzimidazole

Journal of Virology

Volumn 73, Issue 9, 1999, Pages 7271-7277

  Zacny, Valerie L ^a,b   Gershburg, Eduard ^a   Davis, Michelle G ^c   Biron, Karen K ^c   Pagano, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG MECHANISM; EPSTEIN BARR VIRUS; LYMPHOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; SOUTHERN BLOTTING; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0032816076     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.9.7271-7277.1999     Document Type: Article

References (79)

1. Adams, A., and T. Lindahl. 1975. Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc. Natl. Acad. Sci. USA 72:1477-1481.
2. Ben-Bassat, H., N. Goldblum, S. Mitrani, T. Goldblum, J. M. Yoffey, M. M. Cohen, Z. Bentwich, B. Ramot, E. Klein, and G. Klein. 1977. Establishment in continuous culture of a new type of lymphocyte from a 'Burkitt like' malignant lymphoma (line DG-75). Int. J. Cancer 19:27-33.
3. Benz, W. C., P. J. Siegel, and J. Baer. 1978. Effects of adenine arabinoside on lymphocytes infected with Epstein-Barr virus. J. Virol. 27:475-482.
4. Biggen, M., M. Bodescot, M. Perricaudet, and P. Farrell. 1987. Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells. J. Virol. 61:3120-3122.
5. Biron, K. K. Unpublished data.
6. Biron, K. K., M. G. Davis, S. C. Stanat, L. M. Walton, A. Smith, G. W. Koszalka, J. C. Drach, L. B. Townsend, and R. J. Harvey. 1996. Antiviral activity and mechanism of action of 1263W94, a benzimidazole riboside inhibitor of human cytomegalovirus, abstr. H85, p. 178. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Chee, M. S., G. L. Lawrence, and B. G. Barrell. 1989. Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J. Gen. Virol. 70:1151-1160.
8. Chen, L.-W., L.-S. Lin, Y. S. Chang, and S. T. Liu. 1995. Functional analysis of EA-D of Epstein-Barr virus. Virology 211:593-597.
9. Chiou, J. F., J. K. Li, and Y. C. Cheng. 1985. Demonstration of a stimulatory protein for virus-specified DNA polymerase in phorbol ester-treated Epstein-Barr virus-carrying cells. Proc. Natl. Acad. Sci. USA 82:4085-4089.
10. Chow, C. S., and D. M. Coen. 1995. Mutations that specifically impair the DNA binding activity of the herpes simplex virus protein UL42. J. Virol. 69:6965-6971.
11. Coker-Vann, J., and R. Dolin. 1977. Effect of adenine arabinoside on Epstein-Barr virus in vitro. J. Infect. Dis. 135:447-453.
12. Colby, B. M., J. E. Shaw, G. B. Elion, and J. S. Pagano. 1980. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J. Virol. 34:560-568.
13. Coulter, L. J., H. W. Moss, J. Lang, and D. J. McGeoch. 1993. A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted. J. Gen. Virol. 74:387-395.
14. Daibata, M., and T. Sairenji. 1993. Epstein-Bair virus (EBV) replication and expressions of EA-D (BMRF1 gene product), virus-specific deoxyribonuclease, and DNA polymerase in EBV-induced Akata cells. Virology 196:900-904.
15. Daluge, S. M., D. J. M. Purifoy, P. M. Savina, M. H. St. Clair, N. R. Parry, I. K. Dev, P. Novak, K. M. Ayers, J. E. Reardon, G. B. Roberts, J. A. Fyfe, M. R. Blum, D. R. Averett, R. E. Dornsife, B. A. Domin, R. Ferone, D. A. Lewis, and T. A. Krenitsky. 1994. 5-Chloro-2′,3′-dideoxy-3′-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1590-1603.
16. Datta, A. K., and R. E. Hoop. 1981. Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid. Virology 114:52-59.
17. Davis, M. G., C. L. Talarico, M. R. Underwood, F. Baldanti, and K. K. Biron. 1998. Mapping of a mutation in human cytolomegalovirus resistant to 1263W94. Presented at the 23rd International Herpesvirus Workshop, 1-7 Aug. 1998, York, United Kingdom.
18. de The, G. 1982. Epidemiology of Epstein-Barr virus and associated diseases in man, p. 25-103. In B. Roizman (ed.), The herpesviruses. Plenum Press, New York, N.Y.
19. de Wind, N., J. Domen, and A. Berns. 1992. Herpesviruses encode an unusual protein-serine/threonine kinase which is nonessential for growth in cultured cells. J. Virol. 66:5200-5209.
20. Digard, P., C. S. Chow, L. Pirrit, and D. M. Coen. 1993. Functional analysis of the herpes simplex virus UL42 protein. J. Virol. 67:1159-1168.
21. Digard, P., K. P. Williams, P. Hensley, I. S. Brooks, C. E. Dahl, and D. M. Coen. 1995. Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface. Proc. Natl. Acad. Sci. USA 92:1456-1460.
22. Drach, J. C., L. B. Townsend, M. R. Nassiri, S. R. Turk, L. A. Coleman, R. V. Devivar, G. Genzlinger, E. D. Kreske, T. R. Renau, A. C. Westerman, C. Shipman, Jr, K. K. Biron, R. Dornsife, and E. R. Kern. 1992. Benzimidazole ribonucleosides: a new class of antivirals with potent and selective activity against human cytomegalovirus. Antiviral Res 21:49.
23. Drew, W. L., J. P. Lalezari, L. H. Wang, R. C. Miner, J. A. Aberg, M. B. Wire, and M. A. Jacobson. 1998. In vivo anti-CMV activity and safety of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding, abstr. H-25, p. 322. In Program and Abstracts of the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Elion, G. B., P. A. Furman, J. A. Fyfe, P. de Miranda, L. Beauchamp, and H. J. Schaeffer. 1977. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. USA 74:5716-5720.
25. Fixman, E. D., G. S. Hayward, and S. D. Hayward. 1992. trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J. Virol. 66:5030-5039.
26. Gershburg, E. Unpublished data.
27. Hammerschmidt, W., and B. Sugden. 1988. Identification and characterization of orilyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 55:427-433.
28. Harada, H., M. Kitagawa, N. Tanaka, H. Yamamoto, K. Harada, M. Ishihara, and T. Taniguchi. 1993. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 259:971-974.
29. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
30. Heineman, T. C., and J. I. Cohen. 1995. The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. J. Virol. 69:7367-7370.
31. Henle, G., and W. Henle. 1976. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer 17:1-7.
32. Holley-Guthrie, E. A., E. B. Quinlivan, E.-C. Mar, and K. S. 1990. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen D (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:3753-3759.
33. Katz, B. Z., N. Raab-Traub, and G. Miller. 1989. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J. Infect. Dis. 160:589-598.
34. L13 gene of herpes simplex virus 1. J. Virol. 72:1731-1736.
35. Kiehl, A., and D. Dorsky. 1991. Cooperation of DNA polymerase and EA-D (BMRF1) in vitro and colocalization in nuclei of infected cells. Virology 184:330-340.
36. Koszalka, G. W., S. D. Chamberlain, R. J. Harvey, J. C. Drach, L. B. Townsend, and K. K. Biron. 1996. Benzimidazoles for the treatment of human cytomegalovirus. Presented at the Ninth International Conference on Antiviral Research, 19-24 May 1996, Fukushima, Japan.
37. Kurachi, R., T. Daikoku, T. Tsurumi, K. Maeno, Y. Nishiyama, and T. Kurata. 1993. The pathogenicity of a US3 protein kinase-deficient mutant of herpes simplex virus type 2 in mice. Arch. Virol. 133:259-273.
38. Liebowitz, D., and E. Kieff. 1993. Epstein-Barr Virus, p. 107-172. In B. Roizman, R. J. Whitely, and C. Lopez (ed.), The human herpesviruses. Raven Press, New York, N.Y.
39. Lin, J.-C., D. J. Nelson, C. U. Lambe, and E. I. Cho. 1986. Metabolic activation of 9([2-hydroxy-1-hydroxymethyl)ethoxy]methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr virus. J. Virol. 60:569-573.
40. Lin, J. C., E. De Clerq, and J. S. Pagano. 1991. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine, on Epstein-Barr virus replication. Antimicrob. Agents Chemother. 35:2440-2443.
41. Lin, J. C., E. De Clerq, and J. S. Pagano. 1987. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob. Agents Chemother. 31:1431-1433.
42. Lin, J. C., M. Smith, Y. C. Cheng, and J. S. Pagano. 1983. Epstein-Barr virus: inhibition of replication by three new drugs. Science 221:578-579.
43. Lin, J. C., M. C. Smith, E. I. Choi, E. De Clercq, A. Verbruggen, and J. S. Pagano. 1985. Effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine on replication of Epstein-Barr virus in human lymphoblastoid cell lines. Antiviral Res. 1985(Suppl. 1):121-126.
44. Lin, J. C., M. C. Smith, and J. S. Pagano. 1985. Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus. Antimicrob. Agents Chemother. 27:971-973.
45. Lin, J. C., M. C. Smith, and J. S. Pagano. 1984. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J. Virol. 50:50-55.
46. Lopez, C., K. A. Watanabe, and J. J. Fox. 1980. 2′-Fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob. Agents Chemother. 42:963-972.
47. Manet, E., H. Gruffat, M. C. Trescol-Biemont, N. Moreno, P. Chamvard, J. F. Giot, and A. Sergeant. 1989. Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional transactivators. EMBO J. 8:1819-1826.
48. Moffat, J. F., L. Zerboni, M. H. Sommer, T. C. Heineman, J. I. Cohen, H. Kaneshima, and A. M. Arvin. 1998. The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc. Natl. Acad. Sci. USA 95:11969-11974.
49. Ng, T. I., and C. Grose. 1992. Serine protein kinase associated with varicella-zoster virus ORF 47. Virology 191:9-18.
50. Nicholas, J. 1996. Determination and analysis of the complete nucleotide sequence of human herpesvirus 7. J. Virol. 70:5975-5989.
51. Pagano, J. S. 1979. Extrachromosomal DNA, p. 234-248. Academic Press, New York, N.Y.
52. Pagano, J. S. 1995. Epstein-Barr virus: therapy of active and latent infection, p. 155-195. In D. J. Jeffries and E. De Clercq (ed.), Antiviral chemotherapy. John Wiley & Sons Ltd., New York, N.Y.
53. Pagano, J. S., M. Nonoyama, and C.-H. Huang. 1973. Epstein-Barr virus in human cells, p. 218-228. In Possible episomes in eukaryotes: Proceedings of the Fourth Lepetit Colloquium. North-Holland, Amsterdam, The Netherlands.
54. Purves, F. C., W. O. Ogle, and B. Roizman. 1993. Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells. Proc. Natl. Acad. Sci. USA 90:6701-6705.
55. Purves, F. C., and B. Roizman. 1992. The UL13 gene of herpes simplex virus encodes the functions for post-translational processing associated with phosphorylation of the regulatory protein alpha 22. Proc. Natl. Acad. Sci. USA 89:7310-7314.
56. Raab-Traub, N., T. Dambaugh, and E. Kieff. 1980. DNA of Epstein-Barr virus VIII: B95-8, the previous prototype is an unusual deletion derivative. Cell 22:257-267.
57. Raab-Traub, N., and K. Flynn. 1986. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47:883-9.
58. Rea, D., H. J. Delecluse, S. J. Hamilton-Dutoit, L. Marelle, I. Joab, L. Edelman, J. F. Finet, and M. Raphael. 1994. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-Associated Tumors. Ann. Oncol. Suppl. 5:113-116.
59. Rea, D., C. Fourcade, V. Leblond, M. Rowe, I. Joab, L. Edelman, M. O. Bitker, I. Gandjbakhch, C. Suberbielle, J. P. Farcet, et al. 1994. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 58:317-324.
60. Rickinson, A. B., and M. A. Epstein. 1978. Sensitivity of the transforming and replicative function of Epstein-Barr virus to inhibition by phosphonoacetate. J. Gen. Virol. 40:409-420.
61. Russo, J. J., R. A. Bohenzky, M. C. Chien, J. Chen, Y. M. D. Maddalena, J. P. Parry, D. Peruzzi, I. S. Edelman, Y. Chang, and P. S. Moore. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. USA 93:14862-14867.
62. Smith, R. F., and T. F. Smith. 1989. Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. J. Virol. 61:450-455.
63. Summers, W. C., and G. Klein. 1976. Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J. Virol. 18:151-155.
64. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt's lymphoma lines. Int. J. Cancer 33:27-32.
65. Takada, K., and Y. Ono. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 63:445-449.
66. Tamm, I., K. Folkers, C. H. Shunk, and F. L. Horsfall. 1954. Inhibition of influenza virus multiplication by N-glycosides of benzimidazoles. J. Exp. Med. 99:227-250.
67. Tamm, I., and P. B. Sehgal. 1978. Halobenzimidazole ribosides and RNA synthesis of cells and viruses. Adv. Virus Res. 22:187-258.
68. Townsend, L. B. 1992 Benzimidazole ribonucleosides: design, synthesis and evaluation of 2,5,6-trichloro-1-(β-D-ribofuranosyl) benzimidazole (TCRB), 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl) benzimidazole (BDCRB), and some structurally related analogs as agents for human cytomegalovirus infection. Presented at the Fifth International Conference on Antiviral Research, 8-13 March 1992, Vancouver, British Columbia, Canada.
69. Townsend, L. B., R. V. Devovar, S. R. Turk, M. R. Nassiri, and J. C. Drach. 1995. Design, synthesis and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl) benzimidazoles. J. Med. Chem. 38:4098-4105.
70. Tsurumi, T. 1993. Purification and characterization of the DNA-binding activity of the Epstein-Barr virus DNA polymerase accessory protein BMRF1 gene products, as expressed in insect cells by using the baculovirus system. J. Virol. 67:1681-1687.
71. Tsurumi, T., T. Daikoku, R. Kurachi, and Y. Nishiyama. 1993. Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J. Virol. 67:7648-7653.
72. Tsurumi, T., A. Kobayashi, K. Tamai, T. Daikoku, R. Kurachi, and Y. Nishiyama. 1993. Functional expression and characterization of the Epstein-Barr virus DNA polymerase catalytic subunit. J. Virol. 67:4651-4658.
73. Underwood, M. R., R. J. Harvey, S. C. Stanat, M. L. Hemphill, T. Miller, J. C. Drach, L. B. Townsend, and K. K. Biron. 1998. Inhibition of HCMV DNA maturation by a benzimidazole ribonucleotide is mediated through the UL89 gene product. J. Virol. 72:717-725.
74. Wang, L. H., L. Yogendran, S. Weller, P. Sallabank, R. Wiggs, and A. Bye. 1996. A phase I trial evaluating the tolerability and pharmacokinetics of 1263W94 following single oral administration of escalating doses in normal healthy volunteers, abstr. H28, p. 168. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
75. Watanabe, N., J. Sakakibara, A. Hovanessian, T. Taniguchi, and T. Fujita. 1991. Activation of IFN-β promoter element by IRF-1 requires a post-translational event in addition to IRF-1 synthesis. Nucleic Acids Res. 16: 4421-4428.
76. Wong, K.-M., and A. J. Levine. 1986. Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans. J. Virol. 60:149-156.
77. Yajima, Y., A. Tanaka, and M. Nonoyama. 1976. Inhibition of productive replication of Epstein-Barr virus DNA by phosphonoacetic acid. Virology 71:352-354.
78. Zhang, Q., E. Holley-Guthrie, J.-Q. Ge, D. Dorsky, and S. Kenney. 1997. The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV ori-Lyt. Virology 230:22-34.
79. Zhang, Q., Y. Hong, D. Dorsky, E. Holley-Guthrie, S. Zalani, N. A. Elshiekh, A. Kiehl, and S. Kenney. 1996. Functional and physical interaction between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: effects on EBV transcription and lytic replication. J. Virol. 70:5131-5142.